drugset / Trial / NCT06929702

Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children

NCT06929702

Phase 4 Not yet recruiting 58 enrolled University Hospital, Ghent
RandomizedParallel-groupDouble-blindTreatment

Summary

The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem) in critically ill children. This evaluation includes a comparison with the more standard approach on clinical and patient-oriented measures.

Timeline

Start
2025-04-22
Primary completion
2027-10-01
Completion
2027-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified
Subject Meropenem Small molecule

Indications

No indication recorded.